1

FEED-BASED BIVALENT VACCINE AGAINST BACTERIAL DISEASES IN CULTURED FRESHWATER FISHES

VIEW INFOGRAPHICS

Research

THIS PROJECT WILL FOCUS ON IMPROVING A FISH VACCINE, AS WELL AS TESTING ITS STRUCTURAL INTEGRITY, SAFETY, EFFICACY, AND COST-EFFECTIVENESS. THE VACCINE IS FORMULATED TO PROTECT FRESHWATER FISH, SUCH AS TILAPIA, CATFISH, AND STRIPED CATFISH, AGAINST AEROMONAS AND STREPTOCOCCUS INFECTIONS. SPECIFICALLY, THE PROJECT WILL EXPLORE A POST-EXTRUSION SPRAY-COATING METHOD USING A FISH OIL-BASED BINDER, WHICH AIMS TO PROTECT ANTIGEN INTEGRITY, ENHANCE VACCINE STABILITY, AND IMPROVE FISH IMMUNITY

-

RM1,000,000.00

VIEW

2

AVIAN MYCOPLASMA REGIONAL REFERENCE LABORATORY AT INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA

VIEW INFOGRAPHICS

Research

ESTABLISHMENT OF AVIAN MYCOPLASMA REGIONAL REFERENCE LABORATORY AT INSTITUTE OF BIOSCIENCE, UNIVERSITI PUTRA MALAYSIA

-

RM550,000.00

VIEW

3

DEVELOPMENT OF AN INACTIVATED LOW-PATHOGENIC AVIAN INFLUENZA VIRUS H9N2 VACCINE FOR POULTRY

VIEW INFOGRAPHICS

Research

WE HAVE DEVELOPED A PROTOTYPE INACTIVATED WHOLE-VIRUS PREPARATION OF THE MALAYSIAN H9N2 IN A WATER-IN-OIL EMULSION, WHICH INDUCES A STRONG ANTIBODY RESPONSE. THIS VACCINE-INDUCED RESPONSE CAN REDUCE CLOACAL VIRUS SHEDDING FOLLOWING CHALLENGE WITH H9N2, IN SPECIFIC-PATHOGEN-FREE (SPF) CHICKENS VACCINATED TWICE (TLR 6). IN THIS STUDY, THE DEVELOPED H9N2 INACTIVATED VACCINE WILL BE FORMULATED AND MANUFACTURED UNDER A GMP FACILITY. THE INACTIVATED VACCINE WILL BE EVALUATED THROUGH CLINICAL TRIALS ON COMMERCIAL POULTRY FARMS AND IN A VACCINE EFFICACY STUDY AGAINST RECENTLY ISOLATED H9N2 VIRUSES. THE STUDY RESULTS WILL BE USED TO PREPARE VACCINE DOSSIER REPORTS FOR REGISTRATION OF THE INACTIVATED VACCINE WITH THE DEPARTMENT OF VETERINARY SERVICES MALAYSIA (TLR9) FOR COMMERCIALIZATION. THE INACTIVATED VACCINE WILL BE USED AS A PROPHYLAXIS MEASURE TO CONTROL H9N2 IN COMMERCIAL POULTRY IN MALAYSIA AND OTHER COUNTRIES IN THIS REGION.

-

RM399,985.00

VIEW

4

SCALING THE FRONTIER: VALIDATING THE FORMULATION AND PERFORMANCE OF CRISADVAC TO NEUTRALIZE FOWL ADENOVIRUS 8B AT COMMERCIAL SCALE

VIEW INFOGRAPHICS

Research

THE NEXT FRONTIER IN AVIAN HEALTH TRANSITIONS CRISADVAC FROM A LABORATORY PROTOTYPE TO A MARKET-READY SOLUTION FOR FADV-8B. THIS PRE-COMMERCIALIZATION INITIATIVE OPTIMIZES FORMULATION FOR MASS PRODUCTION WHILE VALIDATING SAFETY AND PERFORMANCE AT SCALE USING COMMERCIAL BROILERS. BY NEUTRALIZING THE VIRUS AND OVERCOMING MATERNAL ANTIBODY INTERFERENCE IN REAL-WORLD ENVIRONMENTS, THIS PROJECT DE-RISKS THE TECHNOLOGY FOR STAKEHOLDERS, ENSURING FLOCK UNIFORMITY AND SECURING THE SUPPLY CHAIN AGAINST THE SPECIFIC ECONOMIC THREATS OF INCLUSION BODY HEPATITIS.

-

RM800,000.00

VIEW

5

 

FOOD SUPPLEMENT WITH COMPOSITIONS OF STINGLESS BEE HONEY, EXTRA VIRGIN OLIVE OIL AND BLACK SEED OIL: PI2024000125

IP

-

VIEW